If Critical Path succeeds, pharma gains something it has never had: predictability. "You can design an airplane on a computer
and the airplane flies," says Woodcock. "You can design a skyscraper, a bridge, or whatever, and there are mechanistic predictive
tools to evaluate materials and design. The pharmaceutical industry does not have ways of doing this. I would say [industry
has] been in an existential despair because the science wasn't there. But it's over. We need to focus on applying the science
for drug development in a way that's going to work."